<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512354</url>
  </required_header>
  <id_info>
    <org_study_id>THEVENON PHRC I 2014</org_study_id>
    <nct_id>NCT02512354</nct_id>
  </id_info>
  <brief_title>Contribution of High-throughput Exome Sequencing in the Diagnosis of the Cause Fetal Polymalformation Syndromes</brief_title>
  <acronym>FOETEX</acronym>
  <official_title>Contribution of High-throughput Exome Sequencing in Fetopathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research concerns the contribution of a new examination, high-throughput exome
      sequencing, in the diagnosis of the cause of polymalformative fetal syndromes. With currently
      available examinations, the causes of polyformative syndromes, which correspond to the
      association of several congenital malformations with varying degrees of severity in different
      organs, remain unknown in a large number of cases.

      High-throughput exome sequencing (HTES) is a diagnostic tool that allows the simultaneous
      analysis of all of the coding parts of DNA. This examination has already shown its superior
      diagnostic capability in every post-natal diagnostic context, in particulier in infants with
      malformations associated or not with intellectual deficiency. Its contribution has not yet
      been studied in a large number of fetuses with polymalformations. To investigate the
      usefulness of HTES, we propose to carry out the examination in 100 fetuses with
      polymalformations, as well as the usual examinations including chromosomal microarray
      analysis and possibly the study of specific genes that may explain these malformations. A
      blood sample will be taken from both parents to allow interpretation of the results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2015</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">October 8, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of additional diagnoses made thanks to HTES compared with the usual examinations</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of diagnoses not made by HTES compared with usual examinations</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Fetuses With at Least 2 Malformations, and no Diagnosis After Fetopathological and Radiological Examinations</condition>
  <arm_group>
    <arm_group_label>Fetus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample of a fragment of fetal tissue</intervention_name>
    <arm_group_label>Fetus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parent's blood samples</intervention_name>
    <arm_group_label>Fetus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Fetuses With at Least 2 Malformations, and no Diagnosis After Fetopathological and
        Radiological Examinations
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fetus with at least 2 malformations, with no diagnosis (or several low-certainty
             diagnostic hypotheses, which require several molecular examinations) after
             fetopathological and radiological examinations

          -  Written consent from both parents

          -  Possibility to obtain samples from both parents

        Exclusion Criteria:

          -  Refusal of parents to take part in the study

          -  Parents without National Health Insurance cover

          -  Parents under guardianship or in custody

          -  Impossibility to obtain samples from both parents

          -  Diagnostic hypothesis considered highly probable for which a molecular test cheaper
             that HTES is available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse (Hôpital Emile Muller)</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Reims (Hôpital Maison Blanche)</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG (Hôpital Hautepierre)</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

